This article presents the first Evidence-Based Guideline dedicated specifically to the diagnosis and management of eosinophilic granulomatosis with polyangiitis. The 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of eosinophilic granulomatosis with polyangiitis.

The full picture of post-COVID-19 autoimmune diseases and their prevalence is lacking despite numerous case reports and small series. Two studies that use large cohorts now highlight that SARS-CoV-2 infection is linked to a substantially increased risk of developing a diverse spectrum of new-onset autoimmune diseases.

Understanding why individuals with Down syndrome are highly predisposed to autoimmunity has broad mechanistic and therapeutic implications. New work identifies novel potential mechanistic pathways driving increased autoimmunity-relevant CD11c⁺ B cells and provides the broadest view to date of the repertoire of autoantibodies generated in individuals with Down syndrome.

Magnesium ascorbyl phosphate is a stable derivative of ascorbic acid that has now been shown to promote bone formation via stimulation of the CAMKIIα pathway.

A new treatment for osteoarthritis that combines cells from the patient in vitro prior to intra-articular injection has demonstrated beneficial effects on arthritic joints in a compassionate use study.

In a retrospective study, risk–benefit analyses suggest that primary prophylaxis against Pneumocystis jirovecii pneumonia is beneficial in patients receiving rituximab and high-dose glucocorticoids.

In a retrospective study, biologic DMARD therapy was associated with faster control of immune checkpoint inhibitor-associated arthritis but also with a shorter time to cancer progression, compared with methotrexate therapy.

New research suggests that pharmacological restoration of H3K79 methylation could offer a way to prevent osteoarthritis onset and progression.

Clinical and molecular analysis of autoantibodies against the endonuclease DNase1L3 in patients with systemic lupus erythematosus led to the identification of a subset of pathogenetic antibodies that are cross-reactive with double-stranded DNA.